The first developed molecule aimed to simultaneously activate glucagon and GLP-1 receptors for the treatment of obesity and glucose intolerance [35], improving body weight and glycemic control in a similar manner to exendin-4, a GLP-1 analogue [116]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.